Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart L Fine
Daniel F Martin
Peter Kirkpatrick

Showing results (231-240 of 252) with videos related to

Pageof 26
Sort By:
Ophthalmology. Retina|May 4, 2019
Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth FactorAng Li, Nathaniel B Rieveschl, Felipe F Conti, et al.
Ophthalmology|February 9, 2024
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40Chirag D Jhaveri, Danni Liu, Maureen G Maguire, et al.
JAMA|December 15, 2020
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical TrialAndrew N Antoszyk, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA|May 1, 2019
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical TrialCarl W Baker, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA Ophthalmology|March 30, 2021
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
JAMA|February 7, 2023
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic RetinopathyRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
Ophthalmology|May 14, 2021
Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AHClement K Chan, Calvin E Mein, Adam R Glassman, et al.
JAMA Ophthalmology|August 18, 2022
Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over TimeDennis M Marcus, Paolo S Silva, Danni Liu, et al.
JAMA Ophthalmology|August 18, 2022
Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over TimePaolo S Silva, Dennis M Marcus, Danni Liu, et al.
Ophthalmology. Retina|October 10, 2021
A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE)Judy E Kim, Adam R Glassman, Kristin Josic, et al.
Pageof 26

Showing results (231-240 of 252) with videos related to

Sort By:
Pageof 26
Ophthalmology. Retina|May 4, 2019
Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth FactorAng Li, Nathaniel B Rieveschl, Felipe F Conti, et al.
Ophthalmology|February 9, 2024
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40Chirag D Jhaveri, Danni Liu, Maureen G Maguire, et al.
JAMA|December 15, 2020
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical TrialAndrew N Antoszyk, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA|May 1, 2019
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical TrialCarl W Baker, Adam R Glassman, Wesley T Beaulieu, et al.
JAMA Ophthalmology|March 30, 2021
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical TrialRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
JAMA|February 7, 2023
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic RetinopathyRaj K Maturi, Adam R Glassman, Kristin Josic, et al.
Ophthalmology|May 14, 2021
Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AHClement K Chan, Calvin E Mein, Adam R Glassman, et al.
JAMA Ophthalmology|August 18, 2022
Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over TimeDennis M Marcus, Paolo S Silva, Danni Liu, et al.
JAMA Ophthalmology|August 18, 2022
Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over TimePaolo S Silva, Dennis M Marcus, Danni Liu, et al.
Ophthalmology. Retina|October 10, 2021
A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE)Judy E Kim, Adam R Glassman, Kristin Josic, et al.
Pageof 26